Review the side-effects of Inotuzumab ozogamicin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.
Common: Nausea, stomach pain, headache, fever, chills, tiredness
Gastrointestinal: Vomiting, diarrhea, constipation, stomatitis, reduce appetite, liver damage ranging from increased liver enzymes and bilirubin levels to potentially fatal hepatic veno-occlusive disease
Cardiovascular: Abnormal heart rhythm (QT prolongation), bleeding
Respiratory: Cough, sore throat, difficulty in breathing, nosebleeds
Blood: Low blood counts
Others: Vaginal bleeding, infections, infusion-related reactions, increased risk of post-hematopoeitic stem cell transplant
• Inotuzumab ozogamicin therapy should be initiated in women only when the pregnancy test shows a negative result.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.
Common: Nausea, stomach pain, headache, fever, chills, tiredness
Gastrointestinal: Vomiting, diarrhea, constipation, stomatitis, reduce appetite, liver damage ranging from increased liver enzymes and bilirubin levels to potentially fatal hepatic veno-occlusive disease
Cardiovascular: Abnormal heart rhythm (QT prolongation), bleeding
Respiratory: Cough, sore throat, difficulty in breathing, nosebleeds
Blood: Low blood counts
Others: Vaginal bleeding, infections, infusion-related reactions, increased risk of post-hematopoeitic stem cell transplant
Other Precautions :
• Dose modifications are recommended, or the therapy can be discontinued depending on the occurrence of serious adverse reactions during inotuzumab ozogamicin therapy.• Inotuzumab ozogamicin therapy should be initiated in women only when the pregnancy test shows a negative result.
